(NASDAQ: IRWD) Ironwood Pharmaceuticals's forecast annual revenue growth rate of 5.93% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 35.54%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.43%.
Ironwood Pharmaceuticals's revenue in 2026 is $338,987,000.On average, 6 Wall Street analysts forecast IRWD's revenue for 2026 to be $68,131,444,150, with the lowest IRWD revenue forecast at $49,454,308,688, and the highest IRWD revenue forecast at $78,847,086,628. On average, 4 Wall Street analysts forecast IRWD's revenue for 2027 to be $79,042,301,004, with the lowest IRWD revenue forecast at $74,610,934,660, and the highest IRWD revenue forecast at $82,793,670,604.
In 2028, IRWD is forecast to generate $58,574,073,639 in revenue, with the lowest revenue forecast at $56,277,051,143 and the highest revenue forecast at $60,296,840,511.